Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review
Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants
Y Momozawa, R Sasai, Y Usui, K Shiraishi… - JAMA …, 2022 - jamanetwork.com
Importance The clinical importance of genetic testing ofBRCA1andBRCA2in breast, ovarian,
prostate, and pancreatic cancers is widely recognized. However, there is insufficient …
prostate, and pancreatic cancers is widely recognized. However, there is insufficient …
Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017
NA Li, Y Deng, L Zhou, T Tian, S Yang, Y Wu… - Journal of hematology & …, 2019 - Springer
Background Statistical data on the incidence, mortality, and burden of breast cancer and the
relevant risk factors are valuable for policy-making. We aimed to estimate breast cancer …
relevant risk factors are valuable for policy-making. We aimed to estimate breast cancer …
女性乳腺癌流行病学趋势及危险因素研究进展
张雪， 董晓平， 管雅喆， 任萌， 郭冬利， 贺宇彤 - 肿瘤防治研究, 2021 - zlfzyj.com
摘要乳腺癌是全球女性最常见的癌症, 也是女性癌症死亡的主要原因. 2018
年全球新确诊女性乳腺癌病例约209 万, 死亡人数约63 万. 世界各地区乳腺癌发病率各不相同 …
年全球新确诊女性乳腺癌病例约209 万, 死亡人数约63 万. 世界各地区乳腺癌发病率各不相同 …
Systemic therapy for estrogen receptor–positive, HER2-negative breast cancer
HJ Burstein - New England Journal of Medicine, 2020 - Mass Medical Soc
Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …
Management of male breast cancer: ASCO guideline
MJ Hassett, MR Somerfield, ER Baker… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To develop recommendations concerning the management of male breast
cancer. METHODS ASCO convened an Expert Panel to develop recommendations based …
cancer. METHODS ASCO convened an Expert Panel to develop recommendations based …
[HTML][HTML] Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence
NM Almansour - Frontiers in Molecular Biosciences, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen,
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …
Overall mortality after diagnosis of breast cancer in men vs women
Importance Survival differences between male and female patients with breast cancer have
been reported, but the underlying factors associated with the disparity have not been fully …
been reported, but the underlying factors associated with the disparity have not been fully …
Health psychology: Theory, research and practice
DF Marks, M Murray, A Locke, RA Annunziato… - 2024 - torrossa.com
Welcome to Health Psychology: Theory, Research and Practice (Seventh Edition). This
textbook provides an in-depth introduction to the growing field of health psychology. It is …
textbook provides an in-depth introduction to the growing field of health psychology. It is …